Elevated Lipoprotein(a): Background, Current Insights and Future Potential Therapies

References

• Scanu AM, Nakajima K, Edelstein C. Apolipoprotein(a): structure and biology. Front Biosci. 2001;6:D546–D554.
   PubMed Web of Science ®Google Scholar
• Schmidt K, Noureen A, Kronenberg F, Utermann G. Structure, function, and genetics of lipoprotein (a). J Lipid Res. 2016;57(8):1339–1359. doi:10.1194/jlr.R067314
   PubMed Web of Science ®Google Scholar
• Utermann G, Weber W. Protein composition of Lp(a) lipoprotein from human plasma. FEBS Lett. 1983;154(2):357–361. doi:10.1016/0014-5793(83)80182-3
   PubMed Web of Science ®Google Scholar
• Utermann G, Menzel HJ, Kraft HG, Duba HC, Kemmler HG, Seitz C. Lp(a) glycoprotein phenotypes. Inheritance and relation to Lp(a)-lipoprotein concentrations in plasma. JClinInvest. 1987;80(2):458–465. doi:10.1172/JCI113093
   PubMed Web of Science ®Google Scholar
• Utermann G, Kraft HG, Menzel HJ, Hopferwieser T, Seitz C. Genetics of the quantitative Lp(a) lipoprotein trait. I. Relation of LP(a) glycoprotein phenotypes to Lp(a) lipoprotein concentrations in plasma. Hum Genet. 1988;78(1):41–46.
   PubMed Web of Science ®Google Scholar
• Utermann G, Duba C, Menzel HJ. Genetics of the quantitative Lp(a) lipoprotein trait. II. Inheritance of Lp(a) glycoprotein phenotypes. Hum Genet. 1988;78(1):47–50.
   PubMed Web of Science ®Google Scholar
• Sandholzer C, Hallman DM, Saha N, et al. Effects of the apolipoprotein(a) size polymorphism on the lipoprotein(a) concentration in 7 ethnic groups. Hum Genet. 1991;86(6):607–614.
   PubMed Web of Science ®Google Scholar
• Lackner C, Boerwinkle E, Leffert CC, Rahmig T, Hobbs HH. Molecular basis of apolipoprotein (a) isoform size heterogeneity as revealed by pulsed-field gel electrophoresis. J Clin Invest. 1991;87(6):2153–2161. doi:10.1172/JCI115248
   PubMed Web of Science ®Google Scholar
• Scanu AM. Lipoprotein(a). Link between structure and pathology. Ann Epidemiol. 1992;2(4):407–412.
   PubMedGoogle Scholar
• Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Pentanucleotide repeat polymorphism, lipoprotein(a) levels, and risk of ischemic heart disease. J Clin Endocrinol Metab. 2008;93(10):3769–3776. doi:10.1210/jc.2008-0830
   PubMed Web of Science ®Google Scholar
• Nordestgaard BG, Chapman MJ, Ray K, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31(23):2844–2853. doi:10.1093/eurheartj/ehq386
   PubMed Web of Science ®Google Scholar
• Nordestgaard BG, Langsted A. Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology. J Lipid Res. 2016;57(11):1953–1975. doi:10.1194/jlr.R071233
   PubMed Web of Science ®Google Scholar
• Clarke R, Peden JF, Hopewell JC, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med. 2009;361(26):2518–2528. doi:10.1056/NEJMoa0902604
   PubMed Web of Science ®Google Scholar
• Paquette M, Bernard S, Baass A. SLC22A3 is associated with lipoprotein (a) concentration and cardiovascular disease in familial hypercholesterolemia. Clin Biochem. 2019;66:44–48. doi:10.1016/j.clinbiochem.2019.02.008
   PubMed Web of Science ®Google Scholar
• Trinder M, Uddin MM, Finneran P, Aragam KG, Natarajan P. Clinical utility of Lipoprotein(a) and LPA genetic risk score in risk prediction of incident atherosclerotic cardiovascular disease. JAMA Cardiol. 2020;6(3):287–295. doi:10.1001/jamacardio.2020.5398
   Web of Science ®Google Scholar
• Bourgeois R, Girard A, Perrot N, et al. A comparative analysis of the Lipoprotein(a) and low-density lipoprotein proteomic profiles combining mass spectrometry and Mendelian randomization. CJC Open. 2021;3(4):450–459. doi:10.1016/j.cjco.2020.11.019
   PubMedGoogle Scholar
• Hoekstra M, Chen HY, Rong J, et al. Genome-wide association study highlights APOH as a novel locus for Lipoprotein(a) levels-brief report. Arterioscler Thromb Vasc Biol. 2021;41(1):458–464. doi:10.1161/ATVBAHA.120.314965
   PubMed Web of Science ®Google Scholar
• Frischmann ME, Ikewaki K, Trenkwalder E, et al. In vivo stable-isotope kinetic study suggests intracellular assembly of lipoprotein(a). Atherosclerosis. 2012;225(2):322–327. doi:10.1016/j.atherosclerosis.2012.09.031
   PubMed Web of Science ®Google Scholar
• Becker L, Nesheim ME, Koschinsky ML. Catalysis of covalent Lp(a) assembly: evidence for an extracellular enzyme activity that enhances disulfide bond formation. Biochemistry. 2006;45(32):9919–9928. doi:10.1021/bi060283t
   PubMed Web of Science ®Google Scholar
• Koschinsky ML, Marcovina SM. Structure-function relationships in apolipoprotein(a): insights into lipoprotein(a) assembly and pathogenicity. Curr Opin Lipidol. 2004;15(2):167–174.
   PubMed Web of Science ®Google Scholar
• Hoppichler F, Kraft HG, Sandholzer C, Lechleitner M, Patsch JR, Utermann G. Lipoprotein(a) is increased in triglyceride-rich lipoproteins in men with coronary heart disease, but does not change acutely following oral fat ingestion. Atherosclerosis. 1996;122(1):127–134. doi:10.1016/0021-9150(96)05803-0
   PubMed Web of Science ®Google Scholar
• Moriarty PM, Varvel SA, Gordts PL, McConnell JP, Tsimikas S. Lipoprotein(a) mass levels increase significantly according to APOE genotype: an analysis of 431,239 patients. Arterioscler Thromb Vasc Biol. 2017;37(3):580–588. doi:10.1161/ATVBAHA.116.308704
   PubMed Web of Science ®Google Scholar
• McCormick SPA, Schneider WJ. Lipoprotein(a) catabolism: a case of multiple receptors. Pathology. 2019;51(2):155–164. doi:10.1016/j.pathol.2018.11.003
   PubMed Web of Science ®Google Scholar
• Tsimikas S. A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies. J Am Coll Cardiol. 2017;69(6):692–711. doi:10.1016/j.jacc.2016.11.042
   PubMed Web of Science ®Google Scholar
• Boffa MB, Koschinsky ML. Lipoprotein (a): truly a direct prothrombotic factor in cardiovascular disease? J Lipid Res. 2016;57(5):745–757. doi:10.1194/jlr.R060582
   PubMed Web of Science ®Google Scholar
• Tsimikas S. Lipoprotein(a): novel target and emergence of novel therapies to lower cardiovascular disease risk. Curr Opin Endocrinol Diabetes Obes. 2016;23(2):157–164. doi:10.1097/MED.0000000000000237
   PubMed Web of Science ®Google Scholar
• Edelstein C, Pfaffinger D, Hinman J, et al. Lysine-phosphatidylcholine adducts in kringle V impart unique immunological and potential pro-inflammatory properties to human apolipoprotein(a). J Biol Chem. 2003;278(52):52841–52847. doi:10.1074/jbc.M310425200
   PubMed Web of Science ®Google Scholar
• Berliner JA, Leitinger N, Tsimikas S. The role of oxidized phospholipids in atherosclerosis. J Lipid Res. 2009;50(Suppl):S207–12. doi:10.1194/jlr.R800074-JLR200
   PubMedGoogle Scholar
• Scipione CA, Sayegh SE, Romagnuolo R, et al. Mechanistic insights into Lp(a)-induced IL-8 expression: a role for oxidized phospholipid modification of apo(a). J Lipid Res. 2015;56(12):2273–2285. doi:10.1194/jlr.M060210
   PubMed Web of Science ®Google Scholar
• van der Valk FM, Bekkering S, Kroon J, et al. Oxidized phospholipids on lipoprotein(a) elicit arterial wall inflammation and an inflammatory monocyte response in humans. Circulation. 2016;134(8):611–624. doi:10.1161/CIRCULATIONAHA.116.020838
   PubMed Web of Science ®Google Scholar
• Tsimikas S, Clopton P, Brilakis ES, et al. Relationship of oxidized phospholipids on apolipoprotein B-100 particles to race/ethnicity, apolipoprotein(a) isoform size, and cardiovascular risk factors: results from the Dallas Heart Study. Circulation. 2009;119(13):1711–1719. doi:10.1161/CIRCULATIONAHA.108.836940
   PubMed Web of Science ®Google Scholar
• Schwartz GG, Ballantyne CM, Barter PJ, et al. Association of lipoprotein(a) with risk of recurrent ischemic events following acute coronary syndrome: analysis of the dal-outcomes randomized clinical trial. JAMA Cardiol. 2018;3(2):164–168. doi:10.1001/jamacardio.2017.3833
   PubMed Web of Science ®Google Scholar
• Chan DC, Watts GF, Coll B, Wasserman SM, Marcovina SM, Barrett PHR. Lipoprotein(a) particle production as a determinant of plasma lipoprotein(a) concentration across varying apolipoprotein(a) isoform sizes and background cholesterol-lowering therapy. J Am Heart Assoc. 2019;8(7):e011781. doi:10.1161/JAHA.118.011781
   PubMed Web of Science ®Google Scholar
• Ma L, Waldmann E, Ooi EMM, et al. Lipoprotein (a) and Low-density lipoprotein apolipoprotein B metabolism following apheresis in patients with elevated lipoprotein(a) and coronary artery disease. Eur J Clin Invest. 2019;49(2):e13053. doi:10.1111/eci.13053
   PubMed Web of Science ®Google Scholar
• Croyal M, Blanchard V, Ouguerram K, et al. VLDL (Very-Low-Density Lipoprotein)-Apo E (Apolipoprotein E) may influence Lp(a) (lipoprotein [a]) synthesis or assembly. Arterioscler Thromb Vasc Biol. 2020;40(3):819–829. doi:10.1161/ATVBAHA.119.313877
   PubMed Web of Science ®Google Scholar
• Mefford MT, Marcovina SM, Bittner V, et al. PCSK9 loss-of-function variants and Lp(a) phenotypes among black US adults. J Lipid Res. 2019;60(11):1946–1952. doi:10.1194/jlr.P119000173
   PubMed Web of Science ®Google Scholar
• Emerging Risk Factors Collaboration. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA. 2009;302(4):412–423. doi:10.1001/jama.2009.1063.
   PubMed Web of Science ®Google Scholar
• Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA. 2009;301(22):2331–2339. doi:10.1001/jama.2009.801
   PubMed Web of Science ®Google Scholar
• Langsted A, Nordestgaard BG, Kamstrup PR. Elevated lipoprotein(a) and risk of ischemic stroke. J Am Coll Cardiol. 2019;74(1):54–66. doi:10.1016/j.jacc.2019.03.524
   PubMed Web of Science ®Google Scholar
• Gurdasani D, Sjouke B, Tsimikas S, et al. Lipoprotein(a) and risk of coronary, cerebrovascular, and peripheral artery disease: the EPIC-Norfolk prospective population study. Arterioscler Thromb Vasc Biol. 2012;32(12):3058–3065. doi:10.1161/ATVBAHA.112.255521
   PubMed Web of Science ®Google Scholar
• Langsted A, Kamstrup PR, Benn M, Tybjaerg-Hansen A, Nordestgaard BG. High lipoprotein(a) as a possible cause of clinical familial hypercholesterolaemia: a prospective cohort study. Lancet Diabetes Endocrinol. 2016;4(7):577–587. doi:10.1016/S2213-8587(16)30042-0
   PubMed Web of Science ®Google Scholar
• Wong ND, Cupples LA, Ostfeld AM, Levy D, Kannel WB. Risk factors for long-term coronary prognosis after initial myocardial infarction: the Framingham Study. Am J Epidemiol. 1989;130(3):469–480. doi:10.1093/oxfordjournals.aje.a115360
   PubMed Web of Science ®Google Scholar
• Wong ND, Zhao Y, Sung J, Browne A. Relation of first and total recurrent atherosclerotic cardiovascular disease events to increased lipoprotein(a) levels among statin treated adults with cardiovascular disease. Am J Cardiol. 2021;145:12–17. doi:10.1016/j.amjcard.2020.12.075
   PubMed Web of Science ®Google Scholar
• Kostner KM, Kostner GM, Wierzbicki AS. Is Lp(a) ready for prime time use in the clinic? A pros-and-cons debate. Atherosclerosis. 2018;274:16–22. doi:10.1016/j.atherosclerosis.2018.04.032
   PubMed Web of Science ®Google Scholar
• Pare G, Caku A, McQueen M, et al. Lipoprotein(a) levels and the risk of myocardial infarction among 7 ethnic groups. Circulation. 2019;139(12):1472–1482. doi:10.1161/CIRCULATIONAHA.118.034311
   PubMed Web of Science ®Google Scholar
• Chretien JP, Coresh J, Berthier-Schaad Y, et al. Three single-nucleotide polymorphisms in LPA account for most of the increase in lipoprotein(a) level elevation in African Americans compared with European Americans. J Med Genet. 2006;43(12):917–923. doi:10.1136/jmg.2006.042119
   PubMed Web of Science ®Google Scholar
• Mehta A, Virani SS, Ayers CR, et al. Lipoprotein(a) and family history predict cardiovascular disease risk. J Am Coll Cardiol. 2020;76(7):781–793. doi:10.1016/j.jacc.2020.06.040
   PubMed Web of Science ®Google Scholar
• Ohira T, Schreiner PJ, Morrisett JD, Chambless LE, Rosamond WD, Folsom AR. Lipoprotein(a) and incident ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) study. Stroke. 2006;37(6):1407–1412. doi:10.1161/01.STR.0000222666.21482.b6
   PubMed Web of Science ®Google Scholar
• Burgess S, Ference BA, Staley JR, et al. Association of LPA variants with risk of coronary disease and the implications for lipoprotein(a)-lowering therapies: a Mendelian randomization analysis. JAMA Cardiol. 2018;3(7):619–627. doi:10.1001/jamacardio.2018.1470
   PubMed Web of Science ®Google Scholar
• Huded CP, Shah NP, Puri R, et al. Association of serum lipoprotein (a) levels and coronary atheroma volume by intravascular ultrasound. J Am Heart Assoc. 2020;9(23):e018023. doi:10.1161/JAHA.120.018023
   PubMed Web of Science ®Google Scholar
• Kamstrup PR, Tybjaerg-Hansen A, Nordestgaard BG. Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population. J Am Coll Cardiol. 2014;63(5):470–477. doi:10.1016/j.jacc.2013.09.038
   PubMed Web of Science ®Google Scholar
• Capoulade R, Chan KL, Yeang C, et al. Oxidized phospholipids, lipoprotein(a), and progression of calcific aortic valve stenosis. J Am Coll Cardiol. 2015;66(11):1236–1246. doi:10.1016/j.jacc.2015.07.020
   PubMed Web of Science ®Google Scholar
• Zheng KH, Tsimikas S, Pawade T, et al. Lipoprotein(a) and oxidized phospholipids promote valve calcification in patients with aortic stenosis. J Am Coll Cardiol. 2019;73(17):2150–2162. doi:10.1016/j.jacc.2019.01.070
   PubMed Web of Science ®Google Scholar
• Tsimikas S. Potential causality and emerging medical therapies for lipoprotein(a) and its associated oxidized phospholipids in calcific aortic valve stenosis. Circ Res. 2019;124(3):405–415. doi:10.1161/CIRCRESAHA.118.313864
   PubMed Web of Science ®Google Scholar
• Wierzbicki AS, Viljoen A, Chambers JB. Aortic stenosis and lipids: does intervention work? Curr Opin Cardiol. 2010;25(4):379–384. doi:10.1097/HCO.0b013e3283393c9b
   PubMed Web of Science ®Google Scholar
• Garg PK, Guan W, Karger AB, Steffen BT, Budoff M, Tsai MY. Lipoprotein (a) and risk for calcification of the coronary arteries, mitral valve, and thoracic aorta: the multi-ethnic study of atherosclerosis. J Cardiovasc Comput Tomogr. 2021;15(2):154–160. doi:10.1016/j.jcct.2020.06.002
   PubMed Web of Science ®Google Scholar
• Marcovina SM, Albers JJ. Lipoprotein (a) measurements for clinical application. J Lipid Res. 2016;57(4):526–537. doi:10.1194/jlr.R061648
   PubMed Web of Science ®Google Scholar
• Tsimikas S, Fazio S, Ferdinand KC, et al. NHLBI working group recommendations to reduce lipoprotein(a)-mediated risk of cardiovascular disease and aortic stenosis. J Am Coll Cardiol. 2018;71(2):177–192. doi:10.1016/j.jacc.2017.11.014
   PubMed Web of Science ®Google Scholar
• Moriarty PM, Yeang C, Varvel SA, McConnell JP, Tsimikas S. Removing the lipoprotein (a) from the LDL-C measurement results in a 38% reduction in prevalence of elevated LDL-C at any threshold: implications for the prevalence and diagnosis of LDL-mediated risk. J Am Coll Cardiol. 2018;71(11):A1783. doi:10.1016/S0735-1097(18)32324-6
   Web of Science ®Google Scholar
• Seman LJ, DeLuca C, Jenner JL, et al. Lipoprotein(a)-cholesterol and coronary heart disease in the Framingham Heart Study. Clin Chem. 1999;45(7):1039–1046. doi:10.1093/clinchem/45.7.1039
   PubMed Web of Science ®Google Scholar
• Yeang C, Clopton PC, Tsimikas S. Lipoprotein(a)-cholesterol levels estimated by vertical auto profile correlate poorly with Lp(a) mass in hyperlipidemic subjects: implications for clinical practice interpretation of Lp(a)-mediated risk. J Clin Lipidol. 2016;10(6):1389–1396. doi:10.1016/j.jacl.2016.09.012
   PubMed Web of Science ®Google Scholar
• Konerman M, Kulkarni K, Toth PP, Jones SR. Lipoprotein(a) particle concentration and lipoprotein(a) cholesterol assays yield discordant classification of patients into four physiologically discrete groups. J Clin Lipidol. 2012;6(4):368–373. doi:10.1016/j.jacl.2012.01.004
   PubMed Web of Science ®Google Scholar
• Guadagno PA, Summers Bellin EG, Harris WS, et al. Validation of a lipoprotein(a) particle concentration assay by quantitative lipoprotein immunofixation electrophoresis. Clin Chim Acta. 2015;439:219–224. doi:10.1016/j.cca.2014.10.013
   PubMed Web of Science ®Google Scholar
• Lamon-Fava S, Marcovina SM, Albers JJ, et al. Lipoprotein(a) levels, apo(a) isoform size, and coronary heart disease risk in the Framingham Offspring Study. J Lipid Res. 2011;52(6):1181–1187. doi:10.1194/jlr.M012526
   PubMed Web of Science ®Google Scholar
• Yeang C, Witztum JL, Tsimikas S. Novel method for quantification of lipoprotein(a)-cholesterol: implications for improving accuracy of LDL-C measurements. J Lipid Res. 2021;62:100053. doi:10.1016/j.jlr.2021.100053
   PubMed Web of Science ®Google Scholar
• Fatica EM, Meeusen JW, Vasile VC, Jaffe AS, Donato LJ. Measuring the contribution of Lp(a) cholesterol towards LDL-C interpretation. Clin Biochem. 2020;86:45–51. doi:10.1016/j.clinbiochem.2020.09.007
   PubMed Web of Science ®Google Scholar
• Nordestgaard BG, Langlois MR, Langsted A, et al. Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM. Atherosclerosis. 2020;294:46–61. doi:10.1016/j.atherosclerosis.2019.12.005
   PubMed Web of Science ®Google Scholar
• Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2019;41(1):111–188. doi:10.1093/eurheartj/ehz455
   Web of Science ®Google Scholar
• Wilson DP, Jacobson TA, Jones PH, et al. Use of Lipoprotein(a) in clinical practice: a biomarker whose time has come. A scientific statement from the National Lipid Association. J Clin Lipidol. 2019;13(3):374–392. doi:10.1016/j.jacl.2019.04.010
   PubMed Web of Science ®Google Scholar
• Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. Circulation. 2019;139(25):e1082–e1143. doi:10.1161/CIR.0000000000000625
   PubMed Web of Science ®Google Scholar
• Cegla J, Neely RDG, France M, et al. HEART UK consensus statement on Lipoprotein(a): a call to action. Atherosclerosis. 2019;291:62–70. doi:10.1016/j.atherosclerosis.2019.10.011
   PubMed Web of Science ®Google Scholar
• Gencer B, Kronenberg F, Stroes ES, Mach F. Lipoprotein(a): the revenant. Eur Heart J. 2017;38(20):1553–1560. doi:10.1093/eurheartj/ehx033
   PubMed Web of Science ®Google Scholar
• Varvel S, McConnell JP, Tsimikas S. Prevalence of elevated Lp(a) mass levels and patient thresholds in 532,359 patients in the United States. Arterioscler Thromb Vasc Biol. 2016;36(11):2239–2245. doi:10.1161/ATVBAHA.116.308011
   PubMed Web of Science ®Google Scholar
• Kronenberg F. Human genetics and the causal role of lipoprotein(a) for various diseases. Cardiovasc Drugs Ther. 2016;30(1):87–100. doi:10.1007/s10557-016-6648-3
   PubMed Web of Science ®Google Scholar
• Franchini M, Capuzzo E, Liumbruno GM. Lipoprotein apheresis for the treatment of elevated circulating levels of lipoprotein(a): a critical literature review. Blood Transfus. 2016;14(5):413–418. doi:10.2450/2015.0163-15
   PubMed Web of Science ®Google Scholar
• Roeseler E, Julius U, Heigl F, et al. Lipoprotein apheresis for lipoprotein(a)-associated cardiovascular disease: prospective 5 years of follow-up and apolipoprotein(a) characterization. Arterioscler Thromb Vasc Biol. 2016;36(9):2019–2027. doi:10.1161/ATVBAHA.116.307983
   PubMed Web of Science ®Google Scholar
• Safarova MS, Ezhov MV, Afanasieva OI, et al. Effect of specific lipoprotein(a) apheresis on coronary atherosclerosis regression assessed by quantitative coronary angiography. Atheroscler Suppl. 2013;14(1):93–99. doi:10.1016/j.atherosclerosissup.2012.10.015
   PubMed Web of Science ®Google Scholar
• Wang X, Li J, Ju J, Fan Y, Xu H. Effect of different types and dosages of statins on plasma lipoprotein(a) levels: a network meta-analysis. Pharmacol Res. 2021;163:105275. doi:10.1016/j.phrs.2020.105275
   PubMed Web of Science ®Google Scholar
• Tsimikas S, Gordts P, Nora C, Yeang C, Witztum JL. Statin therapy increases lipoprotein(a) levels. Eur Heart J. 2020;41(24):2275–2284. doi:10.1093/eurheartj/ehz310
   PubMed Web of Science ®Google Scholar
• Khera AV, Everett BM, Caulfield MP, et al. Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). Circulation. 2014;129(6):635–642. doi:10.1161/CIRCULATIONAHA.113.004406
   PubMed Web of Science ®Google Scholar
• Sahebkar A, Simental-Mendia LE, Watts GF, et al. Comparison of the effects of fibrates versus statins on plasma lipoprotein(a) concentrations: a systematic review and meta-analysis of head-to-head randomized controlled trials. BMC Med. 2017;15(1):22. doi:10.1186/s12916-017-0787-7
   PubMedGoogle Scholar
• Sahebkar A, Simental-Mendia LE, Pirro M, et al. Impact of ezetimibe on plasma lipoprotein(a) concentrations as monotherapy or in combination with statins: a systematic review and meta-analysis of randomized controlled trials. Sci Rep. 2018;8(1):17887. doi:10.1038/s41598-018-36204-7
   PubMedGoogle Scholar
• Schaefer EJ, Lamon-Fava S, Jenner JL, et al. Lipoprotein(a) levels and risk of coronary heart disease in men. The lipid research clinics coronary primary prevention trial. JAMA. 1994;271(13):999–1003. doi:10.1001/jama.1994.03510370051031
   PubMed Web of Science ®Google Scholar
• Wang X, Luo S, Gan X, He C, Huang R. Safety and efficacy of ETC-1002 in hypercholesterolaemic patients: a meta-analysis of randomised controlled trials. Kardiol Pol. 2019;77(2):207–216. doi:10.5603/KP.a2019.0013
   PubMed Web of Science ®Google Scholar
• Sahebkar A, Reiner Z, Simental-Mendia LE, Ferretti G, Cicero AF. Effect of extended-release niacin on plasma lipoprotein(a) levels: a systematic review and meta-analysis of randomized placebo-controlled trials. Metabolism. 2016;65(11):1664–1678. doi:10.1016/j.metabol.2016.08.007
   PubMed Web of Science ®Google Scholar
• Croyal M, Ouguerram K, Passard M, et al. Effects of extended-release nicotinic acid on apolipoprotein (a) kinetics in hypertriglyceridemic patients. Arterioscler Thromb Vasc Biol. 2015;35(9):2042–2047. doi:10.1161/ATVBAHA.115.305835
   PubMed Web of Science ®Google Scholar
• Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation. 2004;110(23):3512–3517. doi:10.1161/01.CIR.0000148955.19792.8D
   PubMed Web of Science ®Google Scholar
• Boden WE, Probstfield JL, Anderson T, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365(24):2255–2267. doi:10.1056/NEJMoa1107579
   PubMed Web of Science ®Google Scholar
• HPS THRIVE Collaborative Group. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014;371(3):203–212. doi:10.1056/NEJMoa1300955.
   PubMed Web of Science ®Google Scholar
• Parish S, Hopewell JC, Hill MR, et al. Impact of apolipoprotein(a) isoform size on lipoprotein(a) lowering in the HPS2-THRIVE study. Circ Genom Precis Med. 2018;11(2):e001696. doi:10.1161/CIRCGEN.117.001696
   PubMed Web of Science ®Google Scholar
• Farmakis I, Doundoulakis I, Pagiantza A, et al. Lipoprotein(a) reduction with proprotein convertase subtilisin/kexin type 9 inhibitors: a systematic review and meta-analysis. J Cardiovasc Pharmacol. 2021;77(3):397–407. doi:10.1097/FJC.0000000000000963
   PubMed Web of Science ®Google Scholar
• Watts GF, Chan DC, Somaratne R, et al. Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics. Eur Heart J. 2018;39:2577–2585. doi:10.1093/eurheartj/ehy122
   PubMed Web of Science ®Google Scholar
• O’Donoghue ML, Fazio S, Giugliano RP, et al. Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk. Circulation. 2019;139(12):1483–1492. doi:10.1161/CIRCULATIONAHA.118.037184
   PubMed Web of Science ®Google Scholar
• Ruscica M, Greco MF, Ferri N, Corsini A. Lipoprotein(a) and PCSK9 inhibition: clinical evidence. Eur Heart J. 2020;22(SupplL):L53–L56. doi:10.1093/eurheartj/suaa135
   Google Scholar
• Shapiro MD, Minnier J, Tavori H, et al. Relationship between low-density lipoprotein cholesterol and lipoprotein(a) lowering in response to PCSK9 inhibition with evolocumab. J Am Heart Assoc. 2019;8(4):e010932. doi:10.1161/JAHA.118.010932
   PubMed Web of Science ®Google Scholar
• Bittner VA, Szarek M, Aylward PE, et al. Effect of alirocumab on lipoprotein(a) and cardiovascular risk after acute coronary syndrome. J Am Coll Cardiol. 2020;75(2):133–144. doi:10.1016/j.jacc.2019.10.057
   PubMed Web of Science ®Google Scholar
• Szarek M, Bittner VA, Aylward P, et al. Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial. Eur Heart J. 2020;41(44):4245–4255. doi:10.1093/eurheartj/ehaa649
   PubMed Web of Science ®Google Scholar
• Mahmood T, Minnier J, Ito MK, et al. Discordant responses of plasma low-density lipoprotein cholesterol and lipoprotein(a) to alirocumab: a pooled analysis from 10 ODYSSEY phase 3 studies. Eur J Prev Cardiol. 2020;28(8):816–822. . doi:10.1177/2047487320915803.
   PubMed Web of Science ®Google Scholar
• Ray KK, Stoekenbroek RM, Kallend D, et al. Effect of an siRNA therapeutic targeting PCSK9 on atherogenic lipoproteins: prespecified secondary end points in ORION 1. Circulation. 2018;138(13):1304–1316. doi:10.1161/CIRCULATIONAHA.118.034710
   PubMed Web of Science ®Google Scholar
• Fogacci F, Ferri N, Toth PP, Ruscica M, Corsini A, Cicero AFG. Efficacy and safety of mipomersen: a systematic review and meta-analysis of randomized clinical trials. Drugs. 2019;79(7):751–766. doi:10.1007/s40265-019-01114-z
   PubMed Web of Science ®Google Scholar
• Santos RD, Raal FJ, Catapano AL, Witztum JL, Steinhagen-Thiessen E, Tsimikas S. Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein(a) in various populations with hypercholesterolemia: results of 4 phase III trials. Arterioscler Thromb Vasc Biol. 2015;35(3):689–699. doi:10.1161/ATVBAHA.114.304549
   PubMed Web of Science ®Google Scholar
• Nandakumar R, Matveyenko A, Thomas T, et al. Effects of mipomersen, an apolipoprotein B100 antisense, on lipoprotein (a) metabolism in healthy subjects. J Lipid Res. 2018;59(12):2397–2402. doi:10.1194/jlr.P082834
   PubMed Web of Science ®Google Scholar
• Arsenault BJ, Petrides F, Tabet F, et al. Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascular risk. J Clin Lipidol. 2018;12(1):130–136. doi:10.1016/j.jacl.2017.10.001
   PubMed Web of Science ®Google Scholar
• Nicholls SJ, Ruotolo G, Brewer HB, et al. Evacetrapib alone or in combination with statins lowers lipoprotein(a) and total and small LDL particle concentrations in mildly hypercholesterolemic patients. J Clin Lipidol. 2016;10(3):519–527 e4. doi:10.1016/j.jacl.2015.11.014
   PubMed Web of Science ®Google Scholar
• Thomas T, Zhou H, Karmally W, et al. CETP (Cholesteryl Ester Transfer Protein) inhibition with anacetrapib decreases production of lipoprotein(a) in mildly hypercholesterolemic subjects. Arterioscler Thromb Vasc Biol. 2017;37(9):1770–1775. doi:10.1161/ATVBAHA.117.309549
   PubMed Web of Science ®Google Scholar
• Merki E, Graham MJ, Mullick AE, et al. Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice. Circulation. 2008;118(7):743–753. doi:10.1161/CIRCULATIONAHA.108.786822
   PubMed Web of Science ®Google Scholar
• Graham MJ, Viney N, Crooke RM, Tsimikas S. Antisense inhibition of apolipoprotein (a) to lower plasma lipoprotein (a) levels in humans. J Lipid Res. 2016;57(3):340–351. doi:10.1194/jlr.R052258
   PubMed Web of Science ®Google Scholar
• Tsimikas S, Viney NJ, Hughes SG, et al. Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study. Lancet. 2015;386(10002):1472–1483. doi:10.1016/S0140-6736(15)61252-1
   PubMed Web of Science ®Google Scholar
• Viney NJ, van Capelleveen JC, Geary RS, et al. Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials. Lancet. 2016;388(10057):2239–2253. doi:10.1016/S0140-6736(16)31009-1
   PubMed Web of Science ®Google Scholar
• Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, et al. Safety and efficacy of AKCEA-APO(a)-LRx to lower lipoprotein(a) levels in patients with established cardiovascular disease: a phase 2 dose-ranging trial American Heart Association: scientific sessions 2018; 2021. Available from: https://www.abstractsonline.com/pp8/#!/4682/presentation/59761. Accessed June 1, 2021.
   Google Scholar
• Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, et al. Lipoprotein(a) reduction in persons with cardiovascular disease. N Engl J Med. 2020;382(3):244–255. doi:10.1056/NEJMoa1905239
   PubMed Web of Science ®Google Scholar
• Swerdlow DI, Rider DA, Yavari A, Lindholm MW, Campion GV, Nissen SE. Treatment and prevention of lipoprotein(a)-mediated cardiovascular disease: the emerging potential of RNA interference therapeutics. Cardiovasc Res. 2021;cvab100. doi:10.1093/cvr/cvab100
   Web of Science ®Google Scholar
• Sandmark J, Tigerstrom A, Akerud T, et al. Identification and analyses of inhibitors targeting apolipoprotein(a) kringle domains KIV-7, KIV-10, and KV provide insight into kringle domain function. J Biol Chem. 2020;295(15):5136–5151. doi:10.1074/jbc.RA119.011251
   PubMed Web of Science ®Google Scholar
• Welsh P, Welsh C, Celis-Morales CA, et al. Lipoprotein(a) and cardiovascular disease: prediction, attributable risk fraction, and estimating benefits from novel interventions. Eur J Prev Cardiol. 2020;zwaa063. doi:10.1093/eurjpc/zwaa063
   Web of Science ®Google Scholar
• Nicholls SJ, Tang WH, Scoffone H, et al. Lipoprotein(a) levels and long-term cardiovascular risk in the contemporary era of statin therapy. J Lipid Res. 2010;51(10):3055–3061. doi:10.1194/jlr.M008961
   PubMed Web of Science ®Google Scholar
• Rabar S, Harker M, O’Flynn N, Wierzbicki AS; Guideline Development Group. Lipid modification and cardiovascular risk assessment for the primary and secondary prevention of cardiovascular disease: summary of updated NICE guidance. BMJ. 2014;349:g4356. doi:10.1136/bmj.g4356.
   PubMed Web of Science ®Google Scholar
• Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387–2397. doi:10.1056/NEJMoa1410489
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713–1722. doi:10.1056/NEJMoa1615664
   PubMed Web of Science ®Google Scholar
• Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097–2107. doi:10.1056/NEJMoa1801174
   PubMed Web of Science ®Google Scholar